Novo Nordisk A/S reported a 22% increase in sales to DKK 65.3 billion for Q1 2024, with significant growth in diabetes and obesity care products, driven by GLP-1 treatments. Additionally, they announced plans to acquire manufacturing sites from Novo Holdings A/S, aiming for completion by the end of 2024.